GlaxoSmithKline (GSK) in July made its consumer health products division a separate entity as it transforms into a world-leading biopharmaceutical company. By uniting science, technology and talent, the company is aiming to prevent and treat diseases with innovative vaccines, specialty pharmaceuticals and general medicines.
GSK’s headquarters annually invests NT$192 billion (US$6.07 billion) in research and development, focusing on immune science and advanced technologies in human genetics. GSK’s drug and vaccine development focuses on infectious diseases, HIV, oncology and immunology.
Investing in clinical trial research each year, GSK also brings drug development to Taiwan. It cooperates with 17 medical institutes and research centers in Taiwan to help domestic medical research keep pace with international trends and enhance Taiwan’s status as a center for clinical research in the Asia-Pacific region.
Photo courtesy of GSK Taiwan
GSK has launched a revamped brand identity system, which was modified from its former orange logo consisting of lowercase “gsk” and a beating heart. The new logo adopts gradient orange, capitalized “GSK,” and digital and technological lines. Its design brings out a striking, eye-catching image, while conveying GSK’s goals and ideas for the future.
The arrow in the new logo symbolizes GSK’s combination of digital, social and environmental concerns as a “signal to move ahead together” in the biopharmaceutical industry. The curve in the logo symbolizes the ability of the immune system to adapt to and evolve along with the environment.
GSK’s Taiwan branch was established 43 years ago, and has since protected the health of Taiwanese.
“After transforming the organization, our new ambitions and new purpose is to expand our impact here in Taiwan by protecting and treating more patients, to make GSK a place where people can thrive, where they can succeed, grow and be happy at work, all underpinned by doing everything with integrity and care,” GSK Taiwan vice president and general manager Mick Stanley said.
The newly transformed GSK is focusing on protecting the health of Taiwanese with pharmaceuticals and vaccines, advocating and practicing the values of diversity and inclusion, and caring for employees and practicing sustainable development, all of which form the company’s business philosophy.
Being “ambitious for patients” is part of the corporate culture, which GSK attaches great importance to.
“In addition to ‘ambitious for patients,’ GSK’s culture also emphasizes ‘accountable for impact.’ We hope to expand our impacts on Taiwanese people,” Stanley said. “We hope we can move ahead together to defeat disease with medicines and vaccines.”
GSK provides as many as 50 kinds of prescription medicines and more than 15 kinds of vaccines, for children and adults, and endeavors to do its utmost for the health of Taiwanese.
Every day, 2 million doses of vaccines produced by GSK are administered around the world. In the past few years, GSK has advocated for adult vaccination. For example, GSK Taiwan has recently launched a new vaccine against the herpes zoster virus to protect against shingles.
To help Taiwanese become aware of the necessity of adult vaccination, GSK is working with entities in Taiwan to create and promote comprehensive information and an environment for adult vaccination.
GSK provides vaccines for infectious diseases that could occur at every stage of life. It helps provide proper immune protection against meningitis, quadrivalent influenza, polio, measles and other diseases. In Taiwan, an average of 40 percent of children receive vaccines provided by GSK.
GSK is also concerned about the healthcare challenges faced by Taiwan’s rapidly aging population. Accordingly, GSK has been discussing important policy developments with the government through the American Chamber of Commerce in Taiwan, the European Chamber of Commerce Taiwan and the International Research-Based Pharmaceutical Manufacturers Association, with the aim of helping Taiwan lay a solid foundation for its medical environment in the decades to come.
Additionally, since the invention of the first-ever medicine for the treatment of HIV, GSK has continuously worked to improve the health and quality of life of people living with HIV, and has cooperated with government entities and patient groups.
In addition to vaccines, GSK also leads the industry in the treatment and prevention of diseases such as respiratory illnesses. For people with asthma, chronic obstructive pulmonary disease and other respiratory diseases who need drugs for treatment, GSK helps them with a variety of inhaled medicines.
The world’s first inhaler was developed by GSK.
The company helps more than 2 million people with respiratory diseases every year in Taiwan, and allows them to breathe freely with improved quality of life.
Intel Corp has landed Microsoft Corp as a customer for its made-to-order chip business, marking a key win for an ambitious turnaround effort under chief executive officer Pat Gelsinger. Microsoft plans to use Intel’s 18A manufacturing technology to make a forthcoming chip that the software maker designed in-house, the two companies said at an event on Wednesday. They did not identify the product, but Microsoft recently announced plans for two homegrown chips — a computer processor and an artificial intelligence (AI) accelerator. Intel has been seeking to prove it can compete in the foundry market, where companies produce custom chips for clients. It
The arrival of Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) in Japan’s Kumamoto Prefecture marks the regaining of the area’s pivotal position established during the Meiji Restoration in the 19th century, a local business leader said in an interview with CNA. The first fab of Japan Advanced Semiconductor Manufacturing Inc (JASM), TSMC’s majority-owned manufacturing subsidiary in Kumamoto, is set to open today. After the 1868 Meiji Restoration, Kumamoto was of key importance as it was home to a major garrison national defense. However, that position was ceded to Fukuoka after World War II as Japan turned to foreign trade for post-war economic development,
AI EFFECT: Nvidia CEO Jensen Huang moved up to 21st on the Bloomberg Billionaires Index on Thursday after his wealth skyrocketed by US$9.6 billion to US$69.2 billion The artificial intelligence (AI) mania sparked by Nvidia Corp’s sterling results has given a lift to Asia’s major chipmakers, but it has not closed the valuation gap with their US peers. A Bloomberg gauge tracking Asia’s top semiconductor firms, including Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) and Samsung Electronics Co, widened its under-performance against the Philadelphia Semiconductor Index this week. While the Asian index trades at 17 times forward earnings, the US measure is at 27 times, pushing the gap close to a record after Nvidia’s blowout revenue outlook reinforced investor conviction in the boom in generative AI use. Nvidia’s 8 percent
The sound of gentle tapping filled a jewelry workshop in southern China as a craftsman hammered pine-leaf patterns onto a soft slab of gold in the style of old ink paintings. Elaborate traditional pieces created by master goldsmiths have always been popular in China, bought as gifts for special occasions such as the Lunar New Year or simply as investments. But jewelers are now having to consider a new and fast-growing consumer base — younger people, who are increasingly keen to buy gold, seeing it as a safe investment in uncertain economic times. Key to gold’s popularity is China’s lackluster post-COVID-19 recovery, which